Floatz logo

PEGFILGRASTIM

Aggressive B-cell Lymphoma With Secondary Involvement of the CNS

National Cancer Institute (NCI)protein_peptidePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Aggressive B-cell Lymphoma With Secondary Involvement of the CNS cohort.

Asset / SponsorPhaseRating
Benadryl
National Cancer Institute (NCI)
Phase 1CC
1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)-
National Cancer Institute (NCI)
Phase 1CC
Ketorolac Tromethamine
National Cancer Institute (NCI)
Phase 1CC
FENTANYL
National Cancer Institute (NCI)
Phase 1CC
Venetoclax
National Cancer Institute (NCI)
Phase 1CC

View all 12 →

Same molecule, other indications

PEGFILGRASTIM is also rated in:

Chemotherapy-induced NeutropeniaDormant
BBB
Indicative ·
76 / 100
View asset →
neutropeniaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →